Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
sanofi-aventis (formerly Sanofi-Synthelabo) is developing the oral class III anti-arrhythmic agent dronedarone (Multaq) for the potential treatment and prevention of atrial fibrillation. In June 2005, sanofi-aventis submitted EU and US filings for atrial fibrillation. In October 2002, phase I trials for arrhythmia were reported to be ongoing in Japan.
Sablayrolles
Sylvie
S
Centre de Recherche Pierre Fabre, Division of Cardiovascular Diseases II, Castres, France.
Le Grand
Bruno
B
D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000077764:Dronedarone; D006801:Humans
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone